Follow-The-Filings

Security

CPIX

Cumberland Pharmaceuticals I · COM

Equity holders as of 2025 Q4 (each manager’s latest book)

4 owners 1 exit max 0.0% (Vanguard Group Inc.)

grid → activity →
owners 4
max % 0.0%
tracked value $3M
qoq R 2 E 1

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 0.0% — 411,786 $2M hist
Renaissance Technologies LLC 2026 Q1 stale 0.0% Reduce 0.00 pp 470,696 $2M hist
Two Sigma Investments, LP 2025 Q4 0.0% Exit 0.00 pp 24,485 $97 hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 stale 0.0% Reduce 0.00 pp 16,643 $54 hist
Marshall Wace - Marshall Wace, LLP exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 48,137 $192 hist

4 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.22M $8.5M $11.71M
Gross profit * $3.16M $1.91M $5.05M
Gross margin * 34.2% 22.5% 43.1%
Net income $192,184 -$1.95M $1.26M
Net margin * 2.1% -22.9% 10.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $35.71M $36.45M $37.06M
Total non-current assets * $46.06M $39.13M $39.76M
Total assets $81.78M $75.58M $76.82M
Total current liabilities $27.98M $31.62M $36.74M
Total non-current liabilities * $24.53M $21.42M $15.53M
Total equity $29.6M $22.85M $24.88M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $6.09M -$612,186 $4.93M
Cash from investing -$105,695 $57,842 -$4.71M
Cash from financing -$7.42M $196,904 -$6.75M
Net change in cash -$1.44M -$357,440 -$6.52M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders